A "Hot" Topic in Dyslipidemia Management--"How to Beat a Flush": Optimizing Niacin Tolerability to Promote Long-term Treatment Adherence and Coronary Disease Prevention
- Gemfibrozil and Secondary Prevention of Heart Disease. Kirchner, Jeffrey T. // American Family Physician;11/15/1999, Vol. 60 Issue 8, p2417
Presents an abstract of the study `Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men With Low Levels of High Density Lipoprotein Cholesterol,' by H.B. Rubins et al. which appeared on the August 5, 1999 issue of the `New England Journal of Medicine.'
- Antioxidants, Niacin, and Simvastatin in CHD. Zepf, Bill // American Family Physician;4/1/2002, Vol. 65 Issue 7, p1430
Presents an abstract of the study 'Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease,' by B.G. Brown, et al, published in the November 29, 2001 issue of the 'New England Journal of Medicine.'
- HDL: `Good' cholesterol looks even better. // Consumer Reports on Health;Mar1994, Vol. 6 Issue 3, p28
Discusses the role of high-density lipoproteins (HDL) in predicting coronary risk. Significance of low level of HDL cholesterol; Nature of LDLs; HDL level of men and women; Measurement and determination of HDL; Effect of non-drug approaches to HDL and other lipids. INSET: How to get reliable...
- Benefits of Coronary Prevention: WOSCOPS. Kuritzky, Louis // Internal Medicine Alert;11/29/2007, Vol. 29 Issue 22, p176
The article provides information on the West of Scotland Coronary Prevention Study (STUD) which confirmed the benefits of coronary disease prevention through lowering of low density lipoproteins (LDL).
- LDL: The key to CHD reversal. // Cortlandt Forum;01/25/97, Vol. 10 Issue 1, p93
Claims that low density lipoprotein (LDL) cholesterol may hold the key in reversing mortality rate of coronary heart disease. Example of a study which offer excellent proof for this view; Recommended LDL levels.
- THROMBOXANE CIRCADIAN VARIATION IN CORONARY ARTERY DISEASE: EFFECTS OF LOW-DOSE ASPIRIN IN THE ELDERLY. Fimograni, F. L.; Scoyni, R. M.; Machella, L.; Di Gioacchino, C. F.; Lama, J.; Monteleone, G.; Marigliano, V. // Gerontologist;Oct1996 Supplement, Vol. 36 Issue 1, p95
An abstract is included for the article "Thromboxane Circadian Variation in Coronary Artery Disease: Effects of Low-Dose Aspirin in the Elderly," by F. L. Fimognari, R. M. Scovni, L. Machella, C. F. Di Gioacchino, J. Lama, G. Monteleone, and V. Marialiano.
- Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. Meade, T. W.; Brennan, P. J. // BMJ: British Medical Journal (International Edition);07/01/2000, Vol. 321 Issue 7252, p13
Objective: To determine which groups of patients may derive particular benefit or experience harm from the use of low dose aspirin for the primary prevention of coronary heart disease.Design: Randomised controlled trial.Setting: 108 group practices in the Medical Research Council's general...
- Variability in response to clopidogrel. McLachlan, Andrew J.; Campbell, Terence J. // Australian Prescriber;Jun2010, Vol. 33 Issue 3, p62
The authors reflect on the variability in response to antiplatelet drug clopidogrel, an active metabolite that irreversibly binds to and inhibits the adenosine diphosphate P2Y12 receptor on platelets. They find that the generation of active metabolite concentrations is central to such...
- Where To Draw the Line against Cholesterol. Garber, Alan M. // Annals of Internal Medicine;10/15/89, Vol. 111 Issue 8, p625
Editorial. Comments on the guidelines issued by the Toronto Working Group on Cholesterol Policy in Ontario for detecting and managing hypercholesterolemia. Measurement of low density lipoproteins; Indications for drug therapy; Ways to prevent coronary artery heart disease.